What's happening
This bill amends insurance and public health laws to standardize and allow electronic notification of adverse step therapy determination appeals, specifying required information in the notices.
Why it matters
Improves transparency for patients and providers. by requiring adverse step therapy determination notices to clearly state the clinical review criteria used, alternative drugs considered, and any additional information needed for an appeal—making it easier to understand the reasoning behind coverage denials.
Enables faster, more accessible communication. by allowing insurers to deliver adverse determination notices electronically (via email or member/provider portals), which can reduce delays and improve access compared to traditional mail.
Standardizes appeal information across insurers and plans. , ensuring that all parties receive consistent, detailed instructions on how to appeal adverse step therapy decisions and what evidence or documents are necessary—potentially reducing confusion and administrative burdens.
May affect patient care timelines and administrative workflow. by clarifying requirements for what must be included in denial notifications and explicitly permitting electronic communication, which could help expedite appeals and facilitate quicker access to necessary medications.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Patients seeking step therapy overrides
Denial notices would include the clinical review criteria used and any applicable alternative prescription drugs subject to the step therapy protocol.
Health insurers and utilization review agents
They would have to provide the required denial information but could deliver notices electronically and link to plan websites for criteria and alternative drug information.
Prescribing clinicians
Required disclosure of review criteria and alternative drugs would give them information to assess denials and prepare appeals for patients.
Headline styles
Clarify Step Therapy Notices
Plain English, a few words. Used as the page title.
Sponsors
Assembly Member · Assembly District 108
No co-sponsors yet.
History
- Signed chap.28
- Delivered to governor
- Returned to assembly
- Passed senateVote 59–0
- 3rd reading cal.38
- Substituted for S8038
- Referred to rules
- Delivered to senate
- Passed assembly
- Advanced to third reading cal.214
- Reported
- Referred to insurance
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Clarify Step Therapy Notices
Senate Floor Calendar · Sponsor Neil D. Breslin
Full text
4 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
8501
IN ASSEMBLY
January 4, 2024
Introduced by M. of A. McDONALD -- read once and referred to the Committee on Insurance
AN ACT to amend the insurance law and the public health law, in relation to adverse determinations related to a step therapy protocol override determination; and to repeal certain provisions of the insurance law and the public health law relating thereto
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Paragraph 14 of subsection (a) of section 4902 of the insurance law, as added by a chapter of the laws of 2023 amending the insurance law and the public health law relating to requiring notice of adverse step therapy determinations, as proposed in legislative bills numbers S. 2677-A and A. 463-A, is REPEALED.
§ 2. Paragraph 5 of subsection (a) of section 4902 of the insurance law, as added by chapter 705 of the laws of 1996, subparagraph (ii) as amended by chapter 586 of the laws of 1998, is amended to read as follows:
(5) (i) Establishment of a written procedure to assure that the notice of an adverse determination includes:
[(i)] (A) the reasons for the determination including the clinical rationale, if any;
[(ii)] (B) instructions on how to initiate standard and expedited appeals pursuant to section four thousand nine hundred four of this article and an external appeal pursuant to section four thousand nine hundred fourteen of this article; [and
(iii)] (C) notice of the availability, upon request of the insured or the insured's designee, of the clinical review criteria relied upon to make such determination;
(D) what, if any, additional necessary information must be provided to, or obtained by, the utilization review agent in order to render a decision on appeal; and
(E) for an adverse determination related to a step therapy protocol override determination, information that includes the clinical review criteria relied upon to make such determination and any applicable
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD02500-04-4
alternative prescription drugs subject to the step therapy protocol of the utilization review agent.
(ii) A utilization review agent may provide a notice of an adverse determination related to a step therapy protocol override determination electronically pursuant to subsection (i) of section four thousand nine hundred three of this title, including by electronic mail or through the health care plan's member portal and provider portal. An electronic notice of such an adverse determination may meet the requirements of clause (E) of subparagraph (i) of this paragraph by linking to information posted on the website of the health care plan;
§ 3. Subsection (e-1) of section 4903 of the insurance law, as added by a chapter of the laws of 2023 amending the insurance law and the public health law relating to requiring notice of adverse step therapy determinations, as proposed in legislative bills numbers S. 2677-A and A. 463-A, is REPEALED.
§ 4. Subsection (e) of section 4903 of the insurance law, as added by chapter 705 of the laws of 1996, paragraph 2 as amended by chapter 586 of the laws of 1998, is amended to read as follows:
(e) (1) Notice of an adverse determination made by a utilization review agent shall be in writing and must include:
[(1)] (i) the reasons for the determination including the clinical rationale, if any;
[(2)] (ii) instructions on how to initiate standard appeals and expedited appeals pursuant to section four thousand nine hundred four and an external appeal pursuant to section four thousand nine hundred fourteen of this article; [and
(3)] (iii) notice of the availability, upon request of the insured, or the insured's designee, of the clinical review criteria relied upon to make such determination. Such notice shall also specify what, if any, additional necessary information must be provided to, or obtained by, the utilization review agent in order to render a decision on the appeal; and
(iv) for an adverse determination related to a step therapy protocol override request, information that includes the clinical review criteria relied upon to make such determination and any applicable alternative prescription drugs subject to the step therapy protocol of the utilization review agent.
(2) A utilization review agent may provide notice of an adverse determination related to a step therapy protocol override determination electronically pursuant to subsection (i) of this section, including by electronic mail or through the health care plan's member portal and provider portal. An electronic notice of such an adverse determination may meet the requirements of subparagraph (iv) of paragraph one of this subsection by linking to information posted on the website of the health care plan.
§ 5. Paragraph (l) of subdivision 1 of section 4902 of the public health law, as added by a chapter of the laws of 2023 amending the insurance law and the public health law relating to requiring notice of adverse step therapy determinations, as proposed in legislative bills numbers S. 2677-A and A. 463-A, is REPEALED.
§ 6. Paragraph (e) of subdivision 1 of section 4902 of the public health law, as added by chapter 705 of the laws of 1996, subparagraph (ii) as amended by chapter 586 of the laws of 1998, is amended to read as follows:
(e) (i) Establishment of a written procedure to assure that the notice of an adverse determination includes: [(i)] (1) the reasons for the determination including the clinical rationale, if any; [(ii)] (2) instructions on how to initiate standard and expedited appeals pursuant to section forty-nine hundred four and an external appeal pursuant to section forty-nine hundred fourteen of this article; [and (iii)] (3) notice of the availability, upon request of the enrollee or the enrollee's designee, of the clinical review criteria relied upon to make such determination; (4) what, if any, additional necessary information must be provided to, or obtained by, the utilization review agent in order to render a decision on an appeal; and (5) for an adverse determination related to a step therapy protocol override determination, information that includes the clinical review criteria relied upon to make such determination and any applicable alternative prescription drugs subject to the step therapy protocol of the utilization review agent.
(ii) A utilization review agent may provide notice of an adverse determination related to a step therapy protocol override determination electronically pursuant to subdivision nine of section forty-nine hundred three of this title, including by electronic mail or through the health care plan's member portal and provider portal. An electronic notice of such an adverse determination may meet the requirements of clause five of subparagraph (i) of this paragraph by linking to information posted on the website of the health care plan;
§ 7. Subdivision 5-a of section 4903 of the public health law, as added by a chapter of the laws of 2023 amending the insurance law and the public health law relating to requiring notice of adverse step therapy determinations, as proposed in legislative bills numbers S. 2677-A and A. 463-A, is REPEALED.
§ 8. Subdivision 5 of section 4903 of the public health law, as added by chapter 705 of the laws of 1996, paragraph (b) as amended by chapter 586 of the laws of 1998, is amended to read as follows:
5. (a) Notice of an adverse determination made by a utilization review agent shall be in writing and must include:
[(a)] (i) the reasons for the determination including the clinical rationale, if any;
[(b)] (ii) instructions on how to initiate standard and expedited appeals pursuant to section forty-nine hundred four and an external appeal pursuant to section forty-nine hundred fourteen of this article; [and
(c)] (iii) notice of the availability, upon request of the enrollee, or the enrollee's designee, of the clinical review criteria relied upon to make such determination. Such notice shall also specify what, if any, additional necessary information must be provided to, or obtained by, the utilization review agent in order to render a decision on the appeal; and
(iv) for an adverse determination related to a step therapy protocol override request, information that includes the clinical review criteria relied upon to make such determination and any applicable alternative prescription drugs subject to the step therapy protocol of the utilization review agent.
(b) A utilization review agent may provide notice of an adverse determination related to a step therapy protocol override determination electronically pursuant to subdivision nine of this section, including by electronic mail or through the health care plan's member portal and provider portal. An electronic notice of such an adverse determination may meet the requirements of subparagraph (iv) of paragraph (a) of this subdivision by linking to information posted on the website of the health care plan.
§ 9. This act shall take effect on the same date and in the same manner as a chapter of the laws of 2023 amending the insurance law and the public health law relating to requiring notice of adverse step therapy determinations, as proposed in legislative bills numbers S. 2677-A and A. 463-A, takes effect.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.